Mersana Therapeutics, Inc. (MRSN)
| Previous Close | 2.4700 |
| Open | 2.4800 |
| Bid | 2.4300 x 800 |
| Ask | 2.4800 x 400 |
| Day's Range | 2.4300 - 2.5100 |
| 52 Week Range | 0.8010 - 9.6200 |
| Volume | |
| Avg. Volume | 2,154,569 |
| Market Cap | 300.396M |
| Beta (5Y Monthly) | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation SummitFormat: Fireside chatDate/Time: Wednesday, May 29, 2024, at 9:00 a.m. East
- GlobeNewswire
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024Patient recruitment ongoing in Phase 1 clinical trial of XMT-2056; plan to advance dose escalation in 2024 Continue to expect capital resources will support current operating plan commitments into 2026Conference call today at 8:00 a.m. ET CAMBRIDGE, Mas
- GlobeNewswire
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on May 1, 2024, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 35,100 shares of its common stock
